|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XE24
|
|
gptkbp:brand
|
Iclusig
|
|
gptkbp:CASNumber
|
943319-70-8
|
|
gptkbp:contraindication
|
hypersensitivity to ponatinib
|
|
gptkbp:developedBy
|
resistant or intolerant CML
|
|
gptkbp:discoveredBy
|
gptkb:Ariad_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
22 hours
|
|
gptkbp:hasMolecularFormula
|
C29H27F3N6O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ponatinib
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits PDGFR
inhibits FGFR
inhibits VEGFR
inhibits SRC family kinases
inhibits BCR-ABL
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:sideEffect
|
abdominal pain
fatigue
hypertension
pancreatitis
rash
venous thromboembolism
arterial occlusion
|
|
gptkbp:target
|
T315I mutation
|
|
gptkbp:usedFor
|
gptkb:chronic_myeloid_leukemia
gptkb:Philadelphia_chromosome-positive_acute_lymphoblastic_leukemia
|
|
gptkbp:bfsParent
|
gptkb:CD332
|
|
gptkbp:bfsLayer
|
7
|